Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
deals
3
×
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
startups
vc
3
×
biotech
boston
new york blog main
new york top stories
acetylon pharmaceuticals
ambys medicines
azacitidine
beta-thalassemia
cell therapy
constellation pharmaceuticals
crispr
dacogen
david walt
decitabine
diagnostics
dna
epigenetics
epizyme
farydak
feng zhang
flagship pioneering
fulcrum therapeutics
gene editing
gene therapy
genentech
holger willenbring
illumina
insulated genomic domains
ipo
jeffrey tong
What
medicines
3
×
biotech
diseases
new
startup
aiming
aims
ambys
approach
based
big
bio
called
control
create
crispr
deadly
deal
debuted
debuts
developing
diagnostic
drugs
editing
epigenetic
epigenetics
field
fix
flagship’s
formed
future
gene
heats
high
human
launch
launches
liver
make
morning
Language
unset
Current search:
deals
×
vc
×
medicines
×
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?